Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) shares were down 7.2% during trading on Thursday . The company traded as low as $2.32 and last traded at $2.32. 1,113,844 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 1,476,877 shares. The stock had previously closed at $2.50.
Tharimmune Stock Performance
The firm has a market cap of $87.53 million, a price-to-earnings ratio of -0.58 and a beta of 1.43. The firm has a 50-day moving average price of $3.04 and a two-hundred day moving average price of $3.49.
Institutional Trading of Tharimmune
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Clear Street Group Inc. purchased a new stake in shares of Tharimmune during the 4th quarter worth approximately $5,066,000. XTX Topco Ltd acquired a new position in shares of Tharimmune in the 2nd quarter valued at $25,000. Franklin Resources Inc. purchased a new position in shares of Tharimmune in the 2nd quarter valued at $88,000. Drucker Wealth 3.0 LLC grew its position in shares of Tharimmune by 150.0% in the 4th quarter. Drucker Wealth 3.0 LLC now owns 25,337 shares of the company’s stock valued at $77,000 after buying an additional 15,202 shares during the last quarter. Finally, Essex LLC acquired a new stake in Tharimmune during the 4th quarter worth $31,000. Institutional investors and hedge funds own 1.16% of the company’s stock.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.
Read More
- Five stocks we like better than Tharimmune
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
